New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For THLD;ISRG;GERN;NFLX;ZIOP;ONTY;HWD;XWES;TROX;MRO;HK;STRZA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
November 19, 2014
09:39 EDTNFLXActive equity options trading on open
Subscribe for More Information
09:38 EDTNFLXCCS Insight predicts Netflix to be acquired next year, FT reports
CCS Insight, a U.K.-based technology research firm, is predicting that a major internet player such as Yahoo (YHOO), Alibaba (BABA) or Google (GOOG) will buy Netflix (NFLX) next year, reported Financial Times. Reference Link
06:34 EDTNFLXNielsen to begin measuring viewing of subscription video services, WSJ reports
Subscribe for More Information
06:00 EDTNFLXStocks with implied volatility below IV index mean; PCLN NFLX
Stocks with implied volatility below IV index mean; Priceline (PCLN) 22, Netflix (NFLX) 29 according to iVolatility.
November 18, 2014
17:40 EDTNFLXNetflix to launch in Australia, New Zealand in March, 2015
Subscribe for More Information
05:57 EDTNFLXStocks with implied volatility below IV index mean; PCLN NFLX
Stocks with implied volatility below IV index mean; Priceline (PCLN) 22, Netflix (NFLX) 30 according to iVolatility.
November 17, 2014
11:06 EDTGERNLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:12 EDTMROBloomberg / Mayer Brown to co-host a conference
Subscribe for More Information
07:05 EDTTHLDThreshold Pharmaceuticals announces TH-302, bevacizumab Phase 1/2 interim data
Threshold Pharmaceuticals announced interim data from a U.S. investigator-sponsored Phase 1/2 clinical trial of the investigational anticancer drug TH-302 in combination with bevacizumab for the treatment of glioblastoma, or GBM, the most lethal form of brain cancer. All patients in the study had previously progressed on single-agent bevacizumab, the only FDA-approved therapy for GBM patients with progressive disease following prior therapy. As reported by the investigator, in a total of 22 evaluable patients, best responses included one complete response and three partial responses for a response rate of 18%, and ten stable disease assessments for a clinical benefit rate of 64%; eight patients had progressive disease. Median progression-free survival was 2.8 months, and median overall survival was 4.6 months. In addition, the FDA, through its Office of Orphan Product Development, recently awarded Dr. Brenner a grant for a Phase 2 clinical trial of TH-302 for the treatment of GBM. His is one of 15 grants the FDA awarded in 2014 in order to boost the development of medical device, drug, and biological products for patients with rare diseases. According to the FDA, the grants are for clinical studies on safety and/or effectiveness of products that could either result in, or substantially contribute to, approval of the products.
November 14, 2014
17:07 EDTNFLXSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
17:01 EDTNFLXIcahn Associates gives quarterly update on stakes
Subscribe for More Information
16:21 EDTGERNOn The Fly: Closing Wrap
Subscribe for More Information
16:01 EDTNFLXOptions Update; November 14, 2014
Subscribe for More Information
12:58 EDTGERNOn The Fly: Midday Wrap
Subscribe for More Information
12:48 EDTGERNGeron November volatility up on strategic collaboration with Janssen Biotech
Subscribe for More Information
11:37 EDTNFLXNetflix shuts down public API today, Gigaom reports
Subscribe for More Information
10:00 EDTGERNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:16 EDTGERNOn The Fly: Pre-market Movers
Subscribe for More Information
07:12 EDTGERNGeron upgraded to Overweight from Neutral at Piper Jaffray
Subscribe for More Information
06:19 EDTNFLXStocks with implied volatility below IV index mean; PCLN NFLX
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use